Is Abeona Therapeutics Stock a Good Investment?
Abeona Therapeutics Investment Advice | ABEO |
- Examine Abeona Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Abeona Therapeutics' leadership team and their track record. Good management can help Abeona Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Abeona Therapeutics' business and its evolving consumer preferences.
- Compare Abeona Therapeutics' performance and market position to its competitors. Analyze how Abeona Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Abeona Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Abeona Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Abeona Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Abeona Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Abeona Therapeutics Stock
Researching Abeona Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 69.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.55. Abeona Therapeutics had not issued any dividends in recent years. The entity had 1:25 split on the 5th of July 2022.
To determine if Abeona Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Abeona Therapeutics' research are outlined below:
| Abeona Therapeutics generated a negative expected return over the last 90 days | |
| Abeona Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (63.73 M) with loss before overhead, payroll, taxes, and interest of (31.4 M). | |
| Abeona Therapeutics currently holds about 20.1 M in cash with (56.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Abeona Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by institutions such as insurance companies |
Abeona Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Abeona Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Abeona Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Abeona Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 223.2 M.Basic technical analysis of Abeona Stock
As of the 25th of March, Abeona Therapeutics shows the risk adjusted performance of (0.04), and Mean Deviation of 2.04. Abeona Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Abeona Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abeona Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abeona Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abeona Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Abeona Therapeutics' Outstanding Corporate Bonds
Abeona Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Abeona Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Abeona bonds can be classified according to their maturity, which is the date when Abeona Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ABBOTT LABS 295 Corp BondUS002824BB55 | View | |
| ABBOTT LABS 6 Corp BondUS002824AV29 | View | |
| ABBOTT LABS 53 Corp BondUS002824AY67 | View | |
| US002824BP42 Corp BondUS002824BP42 | View | |
| US002824BQ25 Corp BondUS002824BQ25 | View | |
| ABBOTT LABS 475 Corp BondUS002824BG43 | View | |
| US002824BF69 Corp BondUS002824BF69 | View |
Understand Abeona Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Abeona Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 2.04 | |||
| Coefficient Of Variation | (1,656) | |||
| Standard Deviation | 2.98 | |||
| Variance | 8.9 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.20) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 15.37 | |||
| Value At Risk | (4.84) | |||
| Potential Upside | 6.1 | |||
| Skewness | 0.1136 | |||
| Kurtosis | 2.02 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 2.04 | |||
| Coefficient Of Variation | (1,656) | |||
| Standard Deviation | 2.98 | |||
| Variance | 8.9 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.20) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 15.37 | |||
| Value At Risk | (4.84) | |||
| Potential Upside | 6.1 | |||
| Skewness | 0.1136 | |||
| Kurtosis | 2.02 |
Consider Abeona Therapeutics' intraday indicators
Abeona Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Abeona Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Abeona Therapeutics time-series forecasting models is one of many Abeona Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Abeona Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Abeona Stock media impact
Far too much social signal, news, headlines, and media speculation about Abeona Therapeutics that are available to investors today. That information is available publicly through Abeona media outlets and privately through word of mouth or via Abeona internal channels. However, regardless of the origin, that massive amount of Abeona data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Abeona Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Abeona Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Abeona Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Abeona Therapeutics alpha.
Abeona Therapeutics Corporate Management
| Joseph Vazzano | Chief Officer | Profile | |
| Dmitriy MD | Chief Officer | Profile | |
| Brian Kevany | CTO VP | Profile | |
| Carl Denny | Senior Affairs | Profile | |
| Alison Hardgrove | Vice Resources | Profile | |
| Scott Santiamo | Director Communications | Profile |
Already Invested in Abeona Therapeutics?
The danger of trading Abeona Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abeona Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abeona Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abeona Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Abeona Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.